MCID: FLR001
MIFTS: 50

Filarial Elephantiasis

Categories: Eye diseases, Immune diseases, Infectious diseases, Rare diseases, Skin diseases

Aliases & Classifications for Filarial Elephantiasis

MalaCards integrated aliases for Filarial Elephantiasis:

Name: Filarial Elephantiasis 12 52 15 17
Lymphatic Filariasis 12 74 52 58 54 3 15
Elephantiasis 52 71
Filariasis 52 71
Infection by Wuchereria Bancrofti 71
Wuchereria Bancrofti Infection 52
Bancroftian Filarial Chyluria 12
Malayi Tropical Eosinphilia 52
Bancroftian Elephantiasis 12
Elephantiasis of Eyelid 12
Elephantiasis, Filarial 43
Bancroftian Filariasis 52
Filarial Elephantiases 71
Wuchereriasis 52
Elephantitis 52

Characteristics:

Orphanet epidemiological data:

58
lymphatic filariasis
Inheritance: Not applicable; Prevalence: >1/1000; Age of onset: All ages;

Classifications:

Orphanet: 58  
Rare infectious diseases


External Ids:

Disease Ontology 12 DOID:12211
MeSH 43 D004605
NCIt 49 C128360
SNOMED-CT 67 91586009
ICD10 32 B74.0
ICD10 via Orphanet 33 B74.0 B74.1 B74.2
UMLS via Orphanet 72 C0013884
Orphanet 58 ORPHA2035
UMLS 71 C0013882 C0013884 C0016085 more

Summaries for Filarial Elephantiasis

NIH Rare Diseases : 52 Lymphatic filariasis is a parasitic disease caused by microscopic, thread-like worms that only live in the human lymph system , which maintains the body's fluid balance and fights infections. It is spread from person to person by mosquitoes. Most infected people are asymptomatic and never develop clinical symptoms. A small percentage of people develop lymphedema , which may affect the legs, arms, breasts, and genitalia; bacterial infections that cause hardening and thickening of the skin, called elephantiasis; hydrocele (swelling of the scrotum) in men; and pulmonary tropical eosinophilia syndrome . Treatment may include a yearly dose of medicine, called diethylcarbamazine (DEC); while this drug does not kill all of the adult worms, it prevents infected people from giving the disease to someone else.

MalaCards based summary : Filarial Elephantiasis, also known as lymphatic filariasis, is related to podoconiosis and loiasis, and has symptoms including chyluria An important gene associated with Filarial Elephantiasis is IL10 (Interleukin 10), and among its related pathways/superpathways are Allograft rejection and T cell receptor signaling pathway. The drugs Doxycycline and Anti-Bacterial Agents have been mentioned in the context of this disorder. Affiliated tissues include skin, breast and testes, and related phenotype is endocrine/exocrine gland.

Disease Ontology : 12 A filariasis that is characterized by the thickening of the skin and underlying tissues, especially in the legs, male genitals and female breasts, caused by thread-like parasitic worms Wuchereria bancrofti, Brugia malayi or Brugia timori, which inhabit the lymphatics. These nematodes are transmitted by mosquitoes. Acute symptoms include fever, lymphadenitis, lymphangitis, funiculitis, and epididymitis. Chronic symptoms include abscesses, hyperkeratosis, polyarthritis, hydroceles, lymphedema, and elephantiasis.

CDC : 3 Lymphatic filariasis, considered globally as a neglected tropical disease (NTD), is a parasitic disease caused by microscopic, thread-like worms. The adult worms only live in the human lymph system. The lymph system maintains the body's fluid balance and fights infections. Lymphatic filariasis is spread from person to person by mosquitoes. People with the disease can suffer from lymphedema and elephantiasis and in men, swelling of the scrotum, called hydrocele. Lymphatic filariasis is a leading cause of permanent disability worldwide. Communities frequently shun and reject women and men disfigured by the disease. Affected people frequently are unable to work because of their disability, and this harms their families and their communities.

Wikipedia : 74 Lymphatic filariasis, also known as elephantiasis, is a human disease caused by parasitic worms known as... more...

Related Diseases for Filarial Elephantiasis

Diseases related to Filarial Elephantiasis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 532)
# Related Disease Score Top Affiliating Genes
1 podoconiosis 33.5 STH CNTD1
2 loiasis 33.0 SRCIN1 IL5 IL4 IL13 IL10 FUZ
3 onchocerciasis 32.5 STH SRCIN1 IL5 IL4 IL13
4 hypereosinophilic syndrome 31.4 IL5 IL4 IL13 IL10
5 elephantiasis 31.2 STH SRCIN1 IL5 IL4 IL10 GPT2
6 eosinophilic pneumonia 31.1 IL5 IL4 IL13
7 pulmonary eosinophilia 31.1 IL5 IL4 IL13
8 schistosomiasis 31.1 IL5 IL4 IL13 IL10
9 filariasis 31.1 TLR2 IL5 IL10
10 cytokine deficiency 31.0 IL5 IL13
11 endomyocardial fibrosis 30.9 IL5 IL4 IL10
12 dracunculiasis 30.8 STH MPG EPGN
13 ascaris lumbricoides infection 30.7 STH IL5 IL13 EPGN
14 scabies 30.7 IL5 IL10 CD4
15 cellulitis 30.6 IL5 IL10 CD4
16 chlamydia 30.5 TLR2 IL4 IL10
17 echinococcosis 30.4 TLR2 IL5 IL10
18 poliomyelitis 30.4 IL4 IL10 CD4
19 trypanosomiasis 30.4 TLR2 IL4 IL10
20 leishmaniasis 30.4 TLR2 IL5 IL4 IL13 IL10
21 trachoma 30.3 STH MPG IL4 IL10
22 pulmonary tuberculosis 30.3 TLR2 IL4 IL10
23 strongyloidiasis 30.2 STH IL5 IL13 EPGN CD4
24 trichuriasis 30.2 STH IL13 IL10 EPGN
25 osteomyelitis 30.2 TLR2 IL4 IL10
26 plague 30.2 TLR2 IL10 CD4
27 mucocutaneous leishmaniasis 30.2 IL4 IL10 CD4
28 ige responsiveness, atopic 30.2 IL5 IL4 IL13 IL10
29 paragonimiasis 30.1 IL5 IL13 EPGN
30 b cell deficiency 30.1 IL4 IL10 CD4
31 urticaria 30.1 IL5 IL4 IL13
32 tetanus 30.1 IL5 IL4 IL13 IL10
33 keratoconjunctivitis 30.1 IL5 IL4 IL13
34 angiostrongyliasis 30.1 IL5 IL4 IL13
35 lymphatic system disease 30.1 IL4 IL10 CD4
36 chagas disease 30.1 TLR2 IL4 IL10 CD4
37 lepromatous leprosy 30.1 TLR2 IL4 IL10
38 dengue hemorrhagic fever 30.0 IL4 IL13 IL10
39 posterior uveitis 30.0 IL5 IL4 IL13
40 rheumatic heart disease 30.0 TLR2 IL4 IL10
41 leprosy 3 30.0 TLR2 IL5 IL4 IL10 CD4
42 taeniasis 30.0 STH IL4 IL10 CD4
43 severe combined immunodeficiency 30.0 IL5 IL4 IL13 IL10 CD4
44 yaws 30.0 MPG ADIRF
45 toxic shock syndrome 30.0 TLR2 IL4 IL10
46 urinary schistosomiasis 29.9 STH IL5 IL4 IL13 EPGN
47 visceral leishmaniasis 29.9 TLR2 IL4 IL13 IL10
48 amebiasis 29.9 TLR2 IL4 CD4
49 dysentery 29.9 TLR2 STH IL10 CD4
50 keratitis, hereditary 29.9 TLR2 IL10 CD4

Graphical network of the top 20 diseases related to Filarial Elephantiasis:



Diseases related to Filarial Elephantiasis

Symptoms & Phenotypes for Filarial Elephantiasis

UMLS symptoms related to Filarial Elephantiasis:


chyluria

MGI Mouse Phenotypes related to Filarial Elephantiasis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.28 CD4 CNTD1 EPGN FUZ IL10 IL13

Drugs & Therapeutics for Filarial Elephantiasis

Drugs for Filarial Elephantiasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 38)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
2 Anti-Bacterial Agents Phase 4
3 Antimalarials Phase 4
4
Glycerol Approved, Investigational Phase 3 56-81-5 753
5
Petrolatum Approved, Investigational Phase 3 8009-03-8
6 Protective Agents Phase 3
7 Sodium hypochlorite Phase 3
8 Eusol Phase 3
9 Vitamins Phase 3
10 Reslizumab Approved, Investigational Phase 2
11
Diethylcarbamazine Approved, Investigational, Vet_approved Phase 2 90-89-1 3052
12
Piperaquine Experimental, Investigational Phase 2 4085-31-8 5079497
13
Dihydroartemisinin Experimental, Investigational Phase 2 71939-50-9 6918483
14 Artemisinins Phase 2
15 Artemisinine Phase 2
16 Antibodies, Monoclonal Phase 2
17 Respiratory System Agents Phase 2
18 Anti-Asthmatic Agents Phase 2
19 Immunoglobulins Phase 2
20 Antibodies Phase 2
21 Imatinib Mesylate Phase 2 220127-57-1 123596
22 Protein Kinase Inhibitors Phase 2
23
Romidepsin Approved, Investigational Phase 1 128517-07-7 5352062
24
Emodepside Investigational, Vet_approved Phase 1 155030-63-0
25 Pharmaceutical Solutions Phase 1
26
Polidocanol Approved 9002-92-0
27
Piperazine Approved, Vet_approved 110-85-0 4837
28
Mebendazole Approved, Vet_approved 31431-39-7 4030
29
Sodium citrate Approved, Investigational 68-04-2
30
Permethrin Approved, Investigational 52645-53-1 40326
31
Citric acid Approved, Nutraceutical, Vet_approved 77-92-9 311
32 Anesthetics
33 Sclerosing Solutions
34 Piperazine citrate
35 Citrate
36 DMP 777 157341-41-8
37 Liver Extracts
38 Insect Repellents

Interventional clinical trials:

(show top 50) (show all 64)
# Name Status NCT ID Phase Drugs
1 Impact of Albendazole -Ivermectin Combination Treatment on Wuchereria Bancrofti Infection and Transmission in Mali Completed NCT02784743 Phase 4 ''albendazole'' and ''ivermectin''
2 Comparison Between the Post-Treatment Reactions After Single-dose Ivermectin or DEC in Subjects With Loa Loa Infection Completed NCT01593722 Phase 4 Diethylcarbamazine;Ivermectin
3 Alternate Chemotherapy Regimens for the Clearance of W.Bancrofti Infection: Double Blind Randomised Clinical Trial (RCT) to Study the Efficacy of Different Co-administration and Sequential Administration Completed NCT02005653 Phase 4 Diethylcarbamazine;Albendazole;Doxycycline
4 Cluster Randomized Community-based Trial of Annual Versus Biannual Single-dose Ivermectin Plus Albendazole Against Wuchereria Bancrofti Infection in Human and Mosquito Populations Recruiting NCT03036059 Phase 4 400 μg/kg Ivermectin + 400 mg Albendazole
5 Safety of the Co-administration of Azithromycin, Albendazole and Ivermectin Versus Standard Treatment Regimens During Mass Drug Administration (MDA) in Ethiopia: a Cluster-randomized Trial Not yet recruiting NCT03570814 Phase 4 Administration of Albendazole on Day 1;Administration of Ivermectin on Day 1;Administration of Azithromycin on Day 1;Administration of Azithromycin on Day 15
6 AZIVAL 2: A Double-blind Cluster-randomized Placebo-controlled Study on the Safety of Integrated Treatment of Trachoma and Lymphatic Filariasis in Children and Adults With Azithromycin, Ivermectin and Albendazole Withdrawn NCT01903057 Phase 4 azithromycin;ivermectin;albendazole;placebo
7 Effect of Concomitant Mansonella Perstans Microfilaremia on Immune Responses Following Single Dose Praziquantel in Subjects With Schistosomiasis: A Pilot Study Withdrawn NCT02734186 Phase 4 Praziquantel
8 Repeat Ivermectin Mass Drug Administrations for Control of Malaria: a Pilot Safety and Efficacy Study Completed NCT02509481 Phase 2, Phase 3 Ivermectin;Albendazole
9 A Cluster Randomised Trial of the Safety of Co-Administration of IDA (Ivermectin, Diethylcarbamazine and Albendazole) & Azithromycin for Integrated Treatment of Neglected Tropical Diseases Completed NCT03676140 Phase 3 Albendazole on Day 1;Ivermectin on Day 1;Diethylcarbamazine on day 1;Azithromycin on Day 1;Azithromycin on Day 8
10 A Randomised Controlled Trial to Evaluate the Effect of a New Skin Care Regimen on Skin Barrier Function in Those With Podoconiosis in Ethiopia Completed NCT02839772 Phase 3
11 Comparison of Ivermectin Alone With Albendazole (ALB) Plus Ivermectin (IVM) in Their Efficacy Against Onchocerciasis Completed NCT03238131 Phase 3 Ivermectin;Albendazole
12 Field Studies on the Feasibility of Interrupting the Transmission of Soil-transmitted Helminths (STH) Recruiting NCT03014167 Phase 3 Albendazole
13 A Multi-center, Double-blind, Randomized, 24-month Study, to Compare the Efficacy of Doxycycline Once Daily for 6 Weeks Versus Placebo in Improving Filarial Lymphedema Independent of Active Filarial Infection Active, not recruiting NCT02929134 Phase 3 Doxycycline;Placebo
14 A Multi-center, Double-blind, Randomized, 24-month Study, to Compare the Efficacy of Doxycycline Once Daily for 6 Weeks Versus Placebo in Improving Filarial Lymphedema Independent of Active Filarial Infection Active, not recruiting NCT02929121 Phase 3 Doxycycline;Placebo
15 A Multi-center, Double-blind, Randomized, 24-month Study, to Compare the Efficacy of Doxycycline Once Daily for 6 Weeks Versus Placebo in Improving Filarial Lymphedema Independent of Active Filarial Infection Active, not recruiting NCT02927496 Phase 3 Doxycycline;Placebo
16 Evaluate Triple-Drug Therapy With Diethylcarbamize (DEC), Albendazole (ALB) and Ivermectin (IVM) That Could Accelerate LF Elimination Outside of Africa Completed NCT01975441 Phase 2 Diethylcarbamazine;Albendazole;Ivermectin
17 Effect of Albendazole and Ivermectin Dose on Wuchereria Bancrofti Microfilarial Clearance in Mali: A Randomized, Open Label Study Completed NCT00339417 Phase 2 Albendazole;Ivermectin
18 Effect of Albendazole Dose and Interval on Wuchereria Bancrofti Microfilarial Clearance in India: A Randomized, Open Label Study Completed NCT00375583 Phase 2 DEC/Albendazole
19 A Pharmacokinetic and Pharmacodynamic Evaluation of Co-Administration of IDA (Ivermectin, Diethylcarbamazine and Albendazole) & Azithromycin for Integrated Treatment of Neglected Tropical Diseases Completed NCT03664063 Phase 2 Azithromycin;Albendazole;Ivermectin;Diethylcarbamazine
20 Effect of Albendazole Dose and Interval on Brugia Malayi Microfilarial Clearance in India: A Randomized, Open Label Study Completed NCT00511004 Phase 2 Albendazole;Diethylcarbamazine
21 Treatment of Mansonella Perstans Infection in an Area Coendemic for Lymphatic Filariasis: A Pilot Study of the Effects of Doxycycline Completed NCT00340691 Phase 2 Doxycycline
22 Efficacy and Safety of High-dose Ivermectin for Reducing Malaria Transmission: A Dose Finding Study (IVERMAL) Completed NCT02511353 Phase 2 ivermectin;placebo;dihydroartemisinin-piperaquine
23 A Randomized, Placebo-controlled, Double-Blind Pilot Study of Single-Dose Humanized Anti-IL5 Antibody (Reslizumab) for the Reduction of Eosinophilia Following Diethylcarbamazine Treatment of Loa Loa Infection Completed NCT01111305 Phase 2 Reslizumab;Diethylcarbamazine
24 A Double-Blinded, Randomized, Placebo-Controlled Dose Escalation Study to Examine the Microfilaricidal Kinetics and Safety of Imatinib for the Treatment of Loa Loa (A Pilot Study) Recruiting NCT02644525 Phase 2 Imatinib Mesylate;Placebo
25 Safety and Efficacy of Combination Therapy With Ivermectin, Diethylcarbamazine, and Albendazole (IDA) for Individuals With Onchocerciasis Recruiting NCT04188301 Phase 2 IVM w/ ALB;Single dose of IDA;Three daily doses of IDA
26 Study on Selective Pelvic Lymphadenectomy for IB-IIA Cervical Cancer Recruiting NCT03295526 Phase 2
27 Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Single Dose Treatment With Diethylcarbamazine, Albendazole and Ivermectin in Humans With and Without Wuchereria Bancrofti Infection in Côte d'Ivoire Completed NCT02845713 Phase 1 Ivermectin, Diethylcarbamazine Albendazole (IDA)
28 A Phase 1, Single-Blind, Randomized, Placebo Controlled, Parallel-Group, Multiple-Dose-Escalation Study to Investigate Safety, Tolerability, and Pharmacokinetics of Emodepside (BAY 44-4400) After Oral Dosing in Healthy Male Subjects Completed NCT03383614 Phase 1 LSF emodepside (BAY 44-4400) oral solution (1mg/mL)
29 A Phase 1, Blinded, Randomized, Placebo Controlled, Parallel-Group, Single-Dose, Dose-Escalation Study to Investigate Safety, Tolerability, and Pharmacokinetics of Emodepside (BAY 44-4400) After Oral Dosing in Healthy Male Subjects Completed NCT02661178 Phase 1 emodepside (BAY 44-4400);placebo
30 Phase1,Randomized,Open-Label,Parallel-Group,Relative Bioavailability Study to Investigate PK,Including Food Effect,Safety and Tolerability of Single Doses of New Immediate Release Tablet Formulations of Emodepside (BAY 44-4400),Compared to Oral Solution,in Healthy Male Subjects Completed NCT03383523 Phase 1 Emodepside (BAY 44-4400)
31 Lord´s Procedure Versus Sclerotherapy for Testicular Hydrocele; a Randomized Controlled Study. Unknown status NCT02082613
32 Research for Elimination of Lymphatic Filariasis (ICIDR) Completed NCT00406627
33 Disability and Quality of Life in Patients With Lymphatic Filariasis in Rural Southern India Completed NCT01629771
34 A Pharmacovigilance Study on the Safety of Integrated Treatment of Trachoma and Lymphatic Filariasis in Children and Adults Living in the Sikasso Region of Mali Completed NCT01586169 triple co administration at once of the combination of Albendazole + ivermectin + azithromycin
35 Community Based Safety Study of 2-drug (Diethylcarbamazine and Albendazole) Versus 3-drug (Ivermectin, Diethylcarbamazine and Albendazole) Therapy for Lymphatic Filariasis Completed NCT02899936 3 drug dose - IDA;2 drug dose - DA
36 Studies on the Interaction Between HIV Infection, Lymphatic Filariasis and Diethylcarbamazine Completed NCT00295698 Diethylcarbamazine
37 Alternative Chemotherapies for Lymphatic Filariasis (LF) Treatment and Elimination in Africa [Cote d'Ivoire] Completed NCT02974049 Albendazole;Ivermectin;Diethylcarbamazine
38 Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis: Monitoring Efficacy of Ongoing Treatment Programs in Papua New Guinea Completed NCT03268252
39 Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis Completed NCT01905423 Albendazole and diethylcarbamazine
40 Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis for Ivory Coast Completed NCT02032043 Annual versus Semiannual Albendazole plus Ivermectin MDA
41 Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis for Liberia Completed NCT01905436 Annual versus Semiannual Albendazole plus Ivermectin Mass Drug Administration
42 Community Based Safety Study of 2-drug (Diethylcarbamazine and Albendazole) Versus 3-drug (Ivermectin, Diethylcarbamazine and Albendazole) Therapy for Lymphatic Filariasis, Scabies and Soil Transmitted Helminths in Fiji Completed NCT03177993 3 drug dose - IDA;3 drug dose - IDA with second dose of ivermectin;2 drug dose - DA
43 Determination of the Prevalence of LF Infection in Districts Not Included in LF Control Activities and of the Basis for Integrated Implementation of LF - Onchocerciasis Elimination Strategies in Potentially Co-endemic Areas Completed NCT03131401
44 Evaluation of Antibacterial Soap for Treatment of Lymphedema and Elephantiasis in an Area Endemic for Lymphatic Filariasis Completed NCT00139100 antimicrobial agent in soap
45 Coinfection With Plasmodium Falciparum and Wuchereria Bancrofti: Clinical, Epidemiologic and Immunologic Implications Completed NCT00471666
46 Research for Elimination of Human Filariasis Completed NCT00145223
47 Regulation of Innate and Adaptive Immune Responses in Individuals Infected Concurrently With Malarial and Filarial Parasites Completed NCT00341666
48 Exhaled NO Testing in Filariasis Completed NCT01628497
49 Gaps in Helminth Control: Safety and Efficacy of Drug Combinations Against Triple Infections Completed NCT01050517 albendazole + ivermectin + praziquantel;albendazole + ivermectin + (1 week later) praziquantel
50 Changes in HIV Viral Load in Patients Undergoing Treatment for Filarial Infection Completed NCT00344279

Search NIH Clinical Center for Filarial Elephantiasis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Ivermectin

Cochrane evidence based reviews: elephantiasis, filarial

Genetic Tests for Filarial Elephantiasis

Anatomical Context for Filarial Elephantiasis

MalaCards organs/tissues related to Filarial Elephantiasis:

40
Skin, Breast, Testes, T Cells, Prostate, B Cells, Eye

Publications for Filarial Elephantiasis

Articles related to Filarial Elephantiasis:

(show top 50) (show all 2633)
# Title Authors PMID Year
1
Regulation of parasite antigen-driven immune responses by interleukin-10 (IL-10) and IL-12 in lymphatic filariasis. 54 61
9125556 1997
2
Immunoregulation in human lymphatic filariasis: the role of interleukin 10. 54 61
7501419 1995
3
The genome of Setaria digitata, a cattle nematode closely related to human filarial parasites. 61
32022853 2020
4
Activation of mosquito immunity blocks the development of transmission-stage filarial nematodes. 61
32015105 2020
5
Ivermectin concentration in breastmilk of a woman with Strongyloides stercoralis and human T-lymphotropic virus-I co-infection. 61
31678122 2020
6
Advances in Vaccine Development for Human Lymphatic Filariasis. 61
31864894 2020
7
The rise or fall of neglected tropical diseases in East Asia Pacific. 61
31550453 2020
8
Molecular xenomonitoring as a post-MDA surveillance tool for global programme to eliminate lymphatic filariasis: Field validation in an evaluation unit in India. 61
31978060 2020
9
Frequency and Clinical Significance of Localized Adverse Events following Mass Drug Administration for Lymphatic Filariasis in an Endemic Area in South India. 61
31769393 2020
10
Design and Analysis of Elimination Surveys for Neglected Tropical Diseases. 61
31930383 2020
11
In vivo efficacy of the boron-pleuromutilin AN11251 against Wolbachia of the rodent filarial nematode Litomosoides sigmodontis. 61
31986143 2020
12
Integrated Cross-Sectional Multiplex Serosurveillance of IgG Antibody Responses to Parasitic Diseases and Vaccines in Coastal Kenya. 61
31769388 2020
13
Safety of high-dose ivermectin: a systematic review and meta-analysis. 61
31960060 2020
14
Lymphedema in three previously Wuchereria bancrofti-endemic health districts in Mali after cessation of mass drug administration. 61
31941448 2020
15
Ivermectin as a novel complementary malaria control tool to reduce incidence and prevalence: a modelling study. 61
31948767 2020
16
Antibody response to Schistosoma haematobium and other helminth species in malaria-exposed populations from Burkina Faso. 61
32007449 2020
17
From parasitic disease control to global health: New orientation of the National Institute of Parasitic Diseases, China CDC. 61
31614120 2020
18
Testing a method of sampling for entomological determination of transmission of Wuchereria bancrofti to inform lymphatic filariasis treatment strategy in urban settings. 61
31973747 2020
19
Solid lipid nanoparticle-based dissolving microneedles: A promising intradermal lymph targeting drug delivery system with potential for enhanced treatment of lymphatic filariasis. 61
31655132 2019
20
Surgical Treatment of Advanced Lymphatic Filariasis of Lower Extremity Combining Vascularized Lymph Node Transfer and Excisional Procedures. 61
31038386 2019
21
Drug Repurposing of Bromodomain Inhibitors as Potential Novel Therapeutic Leads for Lymphatic Filariasis Guided by Multispecies Transcriptomics. 61
31796568 2019
22
An Expanded Transmission Assessment Survey to Confirm the Interruption of Lymphatic Filariasis Transmission in Wallis and Futuna. 61
31595868 2019
23
The consequences of Brugia malayi infection on the flight and energy resources of Aedes aegypti mosquitoes. 61
31804546 2019
24
Gender-related factors affecting health seeking for neglected tropical diseases: findings from a qualitative study in Ethiopia. 61
31830026 2019
25
Intra-Rater Reliability and Agreement of the Indurometer When Used to Assess Mid-Calf Tissue Compressibility Among People Affected by Moderate to Severe Lymphedema in Bangladesh and Ethiopia. 61
31859599 2019
26
An insight into the discovery of potent antifilarial leads against lymphatic filariasis. 61
31800381 2019
27
Elimination or Resurgence: Modelling Lymphatic Filariasis After Reaching the 1% Microfilaremia Prevalence Threshold. 61
31853554 2019
28
How community engagement strategies shape participation in mass drug administration programmes for lymphatic filariasis: The case of Luangwa District, Zambia. 61
31774820 2019
29
Study on vector mosquito of zoonotic Brugia malayi in Musi Rawas, South Sumatera, Indonesia. 61
32009751 2019
30
A Mathematical Model for the Transmission Dynamics of Lymphatic Filariasis with Intervention Strategies. 61
31758278 2019
31
Assessment of transmission in areas of uncertain endemicity for lymphatic filariasis in Brazil. 61
31765388 2019
32
Elimination of lymphatic filariasis as a public health problem from the Arab Republic of Egypt. 61
31400299 2019
33
Evaluating the Evidence for Lymphatic Filariasis Elimination. 61
31506245 2019
34
Efficacy and safety of a single dose of ivermectin, diethylcarbamazine and albendazole for treatment of lymphatic filariasis in Côte d'Ivoire: an open-label, randomized, controlled trial. 61
31641754 2019
35
IgG4 antibodies from patients with asymptomatic bancroftian filariasis inhibit the binding of IgG1 and IgG2 to C1q in a Fc-Fc-dependent mechanism. 61
31485865 2019
36
Elimination of onchocerciasis in Africa by 2025: an ambitious target requires ambitious interventions. 61
31578157 2019
37
Comparison of Staging Systems to Assess Lymphedema Caused by Cancer Therapies, Lymphatic Filariasis, and Podoconiosis. 61
30789319 2019
38
Neglected tropical diseases in the People's Republic of China: progress towards elimination. 61
31578147 2019
39
Whatever happened to China's neglected tropical diseases? 61
31578156 2019
40
Molecular evolution of single chain fragment variable (scFv) for diagnosis of lymphatic filariasis. 61
31512046 2019
41
Portable infrared imaging for longitudinal limb volume monitoring in patients with lymphatic filariasis. 61
31584959 2019
42
Coverage of mass drug administration for elimination of lymphatic filariasis in urban Nagpur, Central India: A mixed method study. 61
31681683 2019
43
Human Migration and the Spread of the Nematode Parasite Wuchereria bancrofti. 61
31077328 2019
44
Antifilarial activity of azadirachtin fuelled through reactive oxygen species induced apoptosis: a thorough molecular study on Setaria cervi. 61
30032733 2019
45
Morphological and genetic variation of Wuchereria bancrofti microfilariae in carriers in Thailand, Lao PDR and Myanmar: evaluation using Giemsa-stained thick blood films. 61
31564254 2019
46
Production optimization and biosynthesis revision of corallopyronin A, a potent anti-filarial antibiotic. 61
31340171 2019
47
The division of labour between community medicine distributors influences the reach of mass drug administration: A cross-sectional study in rural Uganda. 61
31483784 2019
48
Systems analysis-based assessment of post-treatment adverse events in lymphatic filariasis. 61
31557154 2019
49
Intestinal UDP-glucuronosyltransferase as a potential target for the treatment and prevention of lymphatic filariasis. 61
31513587 2019
50
Mapping the baseline prevalence of lymphatic filariasis across Nigeria. 61
31522689 2019

Variations for Filarial Elephantiasis

Expression for Filarial Elephantiasis

Search GEO for disease gene expression data for Filarial Elephantiasis.

Pathways for Filarial Elephantiasis

Pathways related to Filarial Elephantiasis according to GeneCards Suite gene sharing:

(show all 17)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.7 IL5 IL4 IL13 IL10 CD4
2
Show member pathways
12.37 TLR2 IL5 IL4 IL10 CD4
3
Show member pathways
12.34 TLR2 IL5 IL4 IL13 IL10 CD4
4
Show member pathways
12.16 TLR2 IL5 IL4 IL13
5
Show member pathways
12.14 IL5 IL4 IL13 IL10
6 11.74 IL5 IL4 CD4
7 11.73 IL5 IL4 IL10 CD4
8 11.64 IL5 IL4 IL13
9 11.56 IL4 IL13 IL10
10 11.49 IL5 IL4 IL13
11 11.47 IL5 IL4 IL10
12 11.46 IL5 IL4 IL13 IL10 CD4
13 11.32 IL4 IL13 IL10
14 11.09 IL5 IL4 IL13
15 11.02 IL5 IL4 IL13 IL10 CD4
16 10.97 IL5 IL4 IL13 IL10
17 10.48 IL5 IL4 IL13 IL10 CD4

GO Terms for Filarial Elephantiasis

Biological processes related to Filarial Elephantiasis according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 cytokine-mediated signaling pathway GO:0019221 9.65 IL5 IL4 IL13 IL10 CD4
2 positive regulation of B cell proliferation GO:0030890 9.54 IL5 IL4 IL13
3 negative regulation of endothelial cell apoptotic process GO:2000352 9.5 IL4 IL13 IL10
4 response to molecule of bacterial origin GO:0002237 9.49 TLR2 IL10
5 positive regulation of MHC class II biosynthetic process GO:0045348 9.48 IL4 IL10
6 negative regulation of tumor necrosis factor biosynthetic process GO:0042536 9.46 IL4 IL10
7 type 2 immune response GO:0042092 9.43 IL4 IL10
8 immune response GO:0006955 9.43 TLR2 IL5 IL4 IL13 IL10 CD4
9 regulation of isotype switching GO:0045191 9.4 IL4 IL10
10 negative regulation of complement-dependent cytotoxicity GO:1903660 9.16 IL4 IL13
11 asparaginyl-tRNA aminoacylation GO:0006421 8.62 NARS2 NARS1

Molecular functions related to Filarial Elephantiasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.46 IL5 IL4 IL13 IL10
2 growth factor activity GO:0008083 9.26 IL5 IL4 IL10 EPGN
3 asparagine-tRNA ligase activity GO:0004816 8.62 NARS2 NARS1

Sources for Filarial Elephantiasis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....